Tower Research Capital LLC TRC Has $32,000 Stock Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Tower Research Capital LLC TRC lowered its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 48.5% in the fourth quarter, Holdings Channel reports. The firm owned 1,189 shares of the company’s stock after selling 1,119 shares during the period. Tower Research Capital LLC TRC’s holdings in Stevanato Group were worth $32,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of STVN. Raymond James & Associates boosted its position in shares of Stevanato Group by 0.9% during the third quarter. Raymond James & Associates now owns 197,316 shares of the company’s stock worth $5,864,000 after purchasing an additional 1,806 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Stevanato Group in the 3rd quarter valued at $255,000. Calamos Wealth Management LLC acquired a new stake in Stevanato Group during the 3rd quarter worth $1,456,000. Conestoga Capital Advisors LLC lifted its holdings in Stevanato Group by 19.7% during the third quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company’s stock worth $134,753,000 after acquiring an additional 746,136 shares in the last quarter. Finally, Fifth Third Bancorp lifted its holdings in Stevanato Group by 70.1% during the third quarter. Fifth Third Bancorp now owns 2,473 shares of the company’s stock worth $73,000 after acquiring an additional 1,019 shares in the last quarter.

Stevanato Group Stock Down 1.3 %

NYSE:STVN traded down €0.36 ($0.39) during trading hours on Friday, reaching €26.45 ($28.44). 277,600 shares of the stock were exchanged, compared to its average volume of 336,883. The stock has a market cap of $7.82 billion, a PE ratio of 44.83, a PEG ratio of 2.96 and a beta of 0.76. Stevanato Group S.p.A. has a twelve month low of €23.00 ($24.73) and a twelve month high of €36.30 ($39.03). The firm has a 50 day moving average of €29.63 and a 200 day moving average of €29.20. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06.

Stevanato Group (NYSE:STVN) last announced its earnings results on Thursday, March 7th. The company reported €0.18 ($0.19) EPS for the quarter, missing the consensus estimate of €0.19 ($0.20) by (€0.01) (($0.01)). The business had revenue of €320.60 million for the quarter, compared to analyst estimates of €326.85 million. Stevanato Group had a return on equity of 14.31% and a net margin of 13.43%. The business’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 EPS. On average, equities analysts expect that Stevanato Group S.p.A. will post 0.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on STVN. BNP Paribas initiated coverage on Stevanato Group in a report on Monday, April 22nd. They issued an “outperform” rating for the company. Stephens reissued an “overweight” rating and set a $38.00 target price on shares of Stevanato Group in a research note on Monday, March 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $30.00 price target on shares of Stevanato Group in a report on Monday, April 22nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Stevanato Group presently has an average rating of “Moderate Buy” and an average target price of €33.63 ($36.16).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.